Durect (NASDAQ:DRRX) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Friday.

A number of other research firms have also recently commented on DRRX. ValuEngine raised Durect from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. HC Wainwright raised Durect from a “neutral” rating to a “buy” rating and raised their price target for the company from $1.50 to $3.50 in a report on Tuesday, March 6th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $2.83.

NASDAQ DRRX opened at $2.11 on Friday. The company has a current ratio of 2.87, a quick ratio of 2.67 and a debt-to-equity ratio of 0.59. Durect has a fifty-two week low of $0.74 and a fifty-two week high of $2.55.

Durect (NASDAQ:DRRX) last posted its quarterly earnings results on Thursday, March 1st. The specialty pharmaceutical company reported $0.05 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.11. The business had revenue of $19.54 million for the quarter, compared to analysts’ expectations of $4.60 million. Durect had a negative return on equity of 44.90% and a negative net margin of 7.51%. sell-side analysts expect that Durect will post -0.2 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company raised its holdings in Durect by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 120,977 shares of the specialty pharmaceutical company’s stock valued at $189,000 after acquiring an additional 13,072 shares during the period. Wells Fargo & Company MN raised its holdings in Durect by 12.7% during the fourth quarter. Wells Fargo & Company MN now owns 472,248 shares of the specialty pharmaceutical company’s stock valued at $435,000 after acquiring an additional 53,236 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in Durect by 61.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 263,476 shares of the specialty pharmaceutical company’s stock valued at $467,000 after acquiring an additional 100,200 shares during the period. Algert Global LLC bought a new stake in Durect during the fourth quarter valued at about $105,000. Finally, SG Americas Securities LLC increased its holdings in shares of Durect by 1,095.1% in the fourth quarter. SG Americas Securities LLC now owns 188,328 shares of the specialty pharmaceutical company’s stock worth $174,000 after purchasing an additional 172,570 shares during the last quarter. 42.89% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades Durect (DRRX) to Buy” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/04/22/bidaskclub-downgrades-durect-drrx-to-buy.html.

Durect Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Receive News & Ratings for Durect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Durect and related companies with MarketBeat.com's FREE daily email newsletter.